Literature DB >> 8042266

Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy.

J Ferguson1, H Zincke, E Ellison, E Bergstrahl, D G Bostwick.   

Abstract

OBJECTIVES: Prostatic intraepithelial neoplasia (PIN) is considered the most likely precursor of prostatic adenocarcinoma. The effect of androgen deprivation therapy on the prevalence of PIN is unknown.
METHODS: We undertook a case-control study of radical retropubic prostatectomies from 24 treated patients and a control group of 24 untreated patients matched for age and clinical stage (all T3). Androgen deprivation therapy included LHRH agonist leuprolide and flutamide (18 patients), diethylstilbestrol (DES) (2 patients), DES with leuprolide and flutamide (1 patients), and orchiectomy (3 patients). Prostatectomy specimens were evaluated for the presence and extent of high-grade PIN according to the number of high-power microscopic fields, and nuclear tumor grade (1 to 4 scale) and Gleason score were also determined.
RESULTS: The prevalence of high-grade PIN in pretreatment transrectal needle biopsies was similar in the treated and untreated groups. The prevalence and extent of high-grade PIN were lower in cases treated with androgen deprivation therapy than controls. Nuclear tumor grade was also lower in treated patients, but there was a paradoxical increase in the Gleason score. The prevalence of aneuploidy in the cancers was similar in both groups.
CONCLUSIONS: These findings suggest that androgen deprivation therapy decreases the prevalence and extent of high-grade PIN.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8042266     DOI: 10.1016/s0090-4295(94)80015-4

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  13 in total

Review 1.  Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents.

Authors:  R Montironi; R Mazzucchelli; J R Marshall; P H Bartels
Journal:  J Clin Pathol       Date:  1999-11       Impact factor: 3.411

Review 2.  High grade prostatic intraepithelial neoplasia is a disease.

Authors:  M S Steiner
Journal:  Curr Urol Rep       Date:  2001-06       Impact factor: 3.092

3.  [Therapy induced regressive changes of prostate cancer].

Authors:  B Helpap; J Köllermann
Journal:  Pathologe       Date:  2004-11       Impact factor: 1.011

4.  Bcl-2 immunoreactivity in prostate tumorigenesis in relation to prostatic intraepithelial neoplasia, grade, hormonal status, metastatic growth and survival.

Authors:  P Stattin; J E Damber; L Karlberg; H Nordgren; A Bergh
Journal:  Urol Res       Date:  1996

5.  [Regressive changes after short-term neoadjuvant antihormonal therapy in prostatic carcinoma: the value of Gleason grading].

Authors:  R Grobholz; A Riester; C G Sauer; M Siegsmund
Journal:  Pathologe       Date:  2006-02       Impact factor: 1.011

Review 6.  Evaluating radical prostatectomy specimens: therapeutic and prognostic importance.

Authors:  D G Bostwick; R Montironi
Journal:  Virchows Arch       Date:  1997-01       Impact factor: 4.064

Review 7.  Precursor lesions for prostate cancer.

Authors:  M R Feneley; C Busch
Journal:  J R Soc Med       Date:  1997-10       Impact factor: 5.344

Review 8.  Pathological changes in prostate lesions after androgen manipulation.

Authors:  R Montironi; C C Schulman
Journal:  J Clin Pathol       Date:  1998-01       Impact factor: 3.411

9.  Bicalutamide 50 mg monotherapy in patients with isolated high-grade PIN: findings in repeat biopsies at 6 months.

Authors:  Aldo V Bono; Roberta Mazzucchelli; Ilaria Ferrari; Antonio Lopez-Beltran; Andrea B Galosi; Liang Cheng; Rodolfo Montironi
Journal:  J Clin Pathol       Date:  2006-07-05       Impact factor: 3.411

Review 10.  High-grade prostatic intraepithelial neoplasia and prostate cancer risk reduction.

Authors:  Mitchell S Steiner
Journal:  World J Urol       Date:  2003-02-21       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.